Cvs Health Corp SEC Filings

CVS Health (CVS) reported a Q3 2025 net loss driven by a non-cash impairment. Total revenues rose to $102.871B from $95.428B a year ago, led by higher product sales and premiums. However, a $5.725B goodwill impairment and higher operating costs pushed operating income to a loss of $3.207B versus income of $832M last year. Net loss attributable to CVS Health was $3.975B (diluted EPS -$3.13), compared with net income of $87M (EPS $0.07) in Q3 2024.

Year to date, revenues reached $296.374B, while net income attributable to CVS Health was a loss of $1.175B (EPS -$0.93). The quarter included a $483M gain on the deconsolidation of a subsidiary and $632M of net investment income. Cash from operations for the first nine months was $7.249B, essentially flat year over year. On the balance sheet, cash and cash equivalents were $9.098B, goodwill declined to $85.478B, and total debt (short-term, current portion of long-term, and long-term) remained significant. As of October 22, 2025, shares outstanding were 1,269,432,485.

CVS Health Corporation furnished an update on its financial performance. The company announced results for the three months ended September 30, 2025, and made the related press release available as Exhibit 99.1 under Item 2.02.

The materials are furnished, not filed, under the Exchange Act, which means they are not subject to Section 18 liability and are not incorporated by reference unless specifically stated.

CVS Health reported insider transactions by its EVP and Chief People Officer. The filing shows indirect purchases of common stock held by a trust for the benefit of the officer’s spouse. Reported trades: 35 shares at $56.47 on 09/09/2024, 10 shares at $62.24 on 10/02/2024, and 35 shares at $56.85 on 10/23/2024. The explanation notes the shares were bought at a broker’s discretion for a managed account and were not previously reported due to a broker error.

Prem S. Shah, EVP and Group President at CVS Health (CVS), surrendered 6,995 shares on 08/31/2025 to satisfy withholding taxes from the vesting and settlement of a restricted stock unit award. The shares were recorded at a price of $73.15 and, after the transaction, Mr. Shah beneficially owned 60,631.677 shares directly. The Form 4 was signed on 09/02/2025 and reflects a routine insider tax-withholding disposition rather than an open-market sale.

Insider transaction: Tilak Mandadi, Executive Vice President and Chief Experience & Technology Officer at CVS Health (CVS), reported a transaction on 08/31/2025 in which 12,834 shares of CVS common stock were disposed at a price of $73.15 per share. The filing states these shares were surrendered to cover withholding taxes upon vesting and settlement of restricted stock units, a routine payroll tax withholding mechanism for equity compensation. Following the transaction Mandadi beneficially owns 63,952 shares directly.

Anne A. Finucane, a director of CVS Health (CVS), reported a sale of company stock that was filed on Form 4. The filing shows a transaction dated 08/20/2025 in which 7,500 shares of Common Stock were disposed of at a reported price of $71.02 per share under transaction code S(1). After the reported sale, the filing lists 22,156 shares beneficially owned indirectly through a trust. The form includes an explanatory note stating the sale was not timely reported due to an administrative error. The document is signed by Anne M. Finucane on 08/29/2025.